NET Patient Foundation Research Abstracts
NPF and NCRAS Public Health England partnership project has been compiling statistics on the incidence, prevalence and survival of NET patients in England using English cancer registry data, with an aim to also access Scottish, Welsh and Northern Irish cancer registry data to also get UK wide statistics.
We carried out four pieces of research in 2017, abstracts for which can be found below:
- The Incidence and Prevalence of Neuroendocrine Tumours in England.
- The 1- year survival rates for Neuroendocrine tumour patients in England.
- Metachronus primary cancers in Neuroendocrine tumour patients.
- Neuroendocrine Tumour patients experiences of support in the community setting across the treatment trajectory.
Presenting symptoms and delay in diagnosis of gastrointestinal and pancreatic Neuroendocrine tumours
Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues – the role for specialist dietitians and nurses
- Assess what symptoms/side effects patients report on SSA’s.
- Assess the severity of symptoms/side effects reported by patients whilst on SSA’s.
- Produce recommendations on how to deal with symptoms commonly experienced by patients on SSA’s.
This study has been accepted to be published in the British Journal of Nursing.
Recent News
Hospital Outreach
Can you help us with reaching out to hospitals? With your help we will be able to highlight the full range of support and services we offer to the hospital teams and encourage them to inform their patients about our services. Our ask of you: By acting as a ‘bridge’...
Rethinking the “Rare”: new paper calls for greater awareness among healthcare professionals
Neuroendocrine Cancer UK are delighted that our article. ‘Are NENs no longer a rare cancer?’ has been published in the March edition of Neuroendocrinology. For the patient community, this article is a powerful step forward. It highlights the need for better...
ENETS attendance and Helpline hours
Helpline closure: Wednesday 5th March 1-4pm and Thursday 6th March 10am – 4pm As some of our team will be attending the European Neuroendocrine Cancer (ENETs) conference 5th-7th March, this will have an impact on our Helpline availability this week. We attend ENETs to...